Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer,
but the average magnitude of these risks is uncertain and may depend on the context. …

… Ellen Warner MD Warner is Associate Professor, Department of Medicine, University of
Toronto and Toronto-Sunnybrook Regional Cancer Centre, Toronto, Canada … Ellen Warner MD …

The purpose of the American Cancer Society/American Society of Clinical Oncology Breast
Cancer Survivorship Care Guideline is to provide recommendations to assist primary care …

ContextCurrent recommendations for women who have a BRCA1 or BRCA2 mutation are to
undergo breast surveillance from age 25 years onward with mammography annually and …

PURPOSE To assess patient preference for oral versus intravenous (iv) palliative chemotherapy
(CT). A strong preference would be an important quality-of-life issue. PATIENTS AND …

Background Prospective data on the risk of recurrence among women with hormone
receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt …

Purpose To estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers
after diagnosis and to determine which factors are predictive of the risk of a second primary …

Background: A sensitive and acceptable screening regimen for women at high risk for breast
cancer is essential. Contrast-enhanced magnetic resonance imaging (MRI) of the breast is …

BACKGROUND: Approximately 2.0%-2.5% of Ashkenazi Jewish women carry one of three
founding mutations in the BRCA1 and BRCA2 genes, and each mutation is associated with a …

BACKGROUND The authors compared the performance of screening mammography versus
magnetic resonance imaging (MRI) in women at genetically high risk for breast cancer. …